Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine.
Read the full study here: https://www.nature.com/articles/s41386-025-02062-x
Hosted on Acast. See acast.com/privacy for more information.
View all episodes
By Springer Nature
4
1515 ratings
Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine.
Read the full study here: https://www.nature.com/articles/s41386-025-02062-x
Hosted on Acast. See acast.com/privacy for more information.
318 Listeners
2,060 Listeners
761 Listeners
123 Listeners
0 Listeners
4 Listeners
537 Listeners
969 Listeners
419 Listeners
822 Listeners
770 Listeners
336 Listeners
130 Listeners
8,507 Listeners
7,222 Listeners
240 Listeners
29,180 Listeners